# A Study of Avastin (Bevacizumab) Plus Taxane-Based Therapy in Patients With Locally Recurrent or Metastatic Breast Cancer.

> **NCT00448591** · PHASE3 · COMPLETED · sponsor: **Hoffmann-La Roche** · enrollment: 2296 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** bevacizumab [Avastin]
- **DRUG:** Taxane-based chemotherapy

## Key facts

- **NCT ID:** NCT00448591
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-09
- **Primary completion:** 2013-02
- **Final completion:** 2013-02
- **Target enrollment:** 2296 (ACTUAL)
- **Last updated:** 2015-05-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00448591

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00448591, "A Study of Avastin (Bevacizumab) Plus Taxane-Based Therapy in Patients With Locally Recurrent or Metastatic Breast Cancer.". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00448591. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*